ArticleClinical pharmacology and therapeutics2021

Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence".

Stefanie L Groenland et al.PubMed ↗Publisher ↗

No numbers read from the abstract.